Modus Therapeutics

Bergs Securities is proud to have acted as financial adviser and sole bookrunner to Modus Therapeutics in its SEK 8 million directed issue.

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.